Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-week treatment, multi-center, randomized, double-blind, double- dummy, placebo-controlled, parallel-group study to assess the efficacy, and safety of indacaterol (150 microg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 microg b.i.d.) as an active control.

Next Previous
X
Search
Trial Profile

A 26-week treatment, multi-center, randomized, double-blind, double- dummy, placebo-controlled, parallel-group study to assess the efficacy, and safety of indacaterol (150 microg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 microg b.i.d.) as an active control.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms INLIGHT-2
  • Sponsors Novartis

    • Most Recent Events

    • 24 May 2017 Results (n=8445) of a pooled analysis from 11 Phase III/IIIb indacaterol studies assessing the efficacy and safety of once-daily indacaterol 150 and 300 ug in elderly patients with moderate to severe COPD, published in the Respiratory Medicine.
    • 04 Jul 2012 Company added in the association field as reported by EudraCT.
    • 23 Jun 2010 New source identified and integrated (Clinical Trials Registry - India).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top